DSpace@İnönü

Yazar "Namdaroglu, S" için Araştırma Çıktıları | Pubmed İndeksli Yayınlar Koleksiyonu listeleme

Yazar "Namdaroglu, S" için Araştırma Çıktıları | Pubmed İndeksli Yayınlar Koleksiyonu listeleme

Sırala: Sıra: Sonuçlar:

  • The clinical characteristics and therapeutic outcomes of elderly 
    Korkmaz, S; Dal, MS; Berber, I; Sahin, DG; Dogu, MH; Ayyildiz, O; Nizam, I; Albayrak, M; Esen, R; Namdaroglu, S; Sencan, M; Akay, OM; Hacioglu, SK; Yildirim, R; Eser, A; Tombak, A; Pala, C; Ilhan, O (2014)
  • The clinical characteristics and therapeutic outcomes of elderly 
    Korkmaz, S; Dal, MS; Berber, I; Sahin, DG; Dogu, MH; Ayyildiz, O; Nizam, I; Albayrak, M; Esen, R; Namdaroglu, S; Sencan, M; Akay, OM; Hacioglu, SK; Yildirim, R; Eser, A; Tombak, A; Pala, C; Ilhan, O (2014)
  • The clinical characteristics and therapeutic outcomes of elderly 
    Korkmaz, S; Dal, MS; Berber, I; Sahin, DG; Dogu, MH; Ayyildiz, O; Nizam, I; Albayrak, M; Esen, R; Namdaroglu, S; Sencan, M; Akay, OM; Hacioglu, SK; Yildirim, R; Eser, A; Tombak, A; Pala, C; Ilhan, O (2014)
  • Clinical characteristics and therapeutic outcomes of elderly patients 
    Korkmaz, S; Dal, MS; Berber, I; Sahin, DG; Dogu, MH; Ayyildiz, O; Nizam, I; Albayrak, M; Esen, R; Namdaroglu, S; Sencan, M; Akay, OM; Hacioglu, S; Yildirim, R; Eser, A; Tombak, A; Pala, C; Ilhan, O (2015)
    AimsWe aimed to investigate whether older age leads to limitations in the starting dose of imatinib in daily treatment of chronic myeloid leukemia, and to determine the compliance of elderly patients with tyrosine kinase ...
  • Clinical characteristics and therapeutic outcomes of elderly patients 
    Korkmaz, S; Dal, MS; Berber, I; Sahin, DG; Dogu, MH; Ayyildiz, O; Nizam, I; Albayrak, M; Esen, R; Namdaroglu, S; Sencan, M; Akay, OM; Hacioglu, S; Yildirim, R; Eser, A; Tombak, A; Pala, C; Ilhan, O (2015)
    AimsWe aimed to investigate whether older age leads to limitations in the starting dose of imatinib in daily treatment of chronic myeloid leukemia, and to determine the compliance of elderly patients with tyrosine kinase ...
  • Clinical characteristics and therapeutic outcomes of elderly patients 
    Korkmaz, S; Dal, MS; Berber, I; Sahin, DG; Dogu, MH; Ayyildiz, O; Nizam, I; Albayrak, M; Esen, R; Namdaroglu, S; Sencan, M; Akay, OM; Hacioglu, S; Yildirim, R; Eser, A; Tombak, A; Pala, C; Ilhan, O (2015)
    AimsWe aimed to investigate whether older age leads to limitations in the starting dose of imatinib in daily treatment of chronic myeloid leukemia, and to determine the compliance of elderly patients with tyrosine kinase ...
  • A Multicenter Experience of Thrombotic Microangiopathies in Turkey: The 
    Tekgunduz, E; Yilmaz, M; Erkurt, MA; Kiki, I; Kaya, AH; Kaynar, L; Alacacioglu, I; Cetin, G; Ozarslan, I; Kuku, I; Sincan, G; Salim, O; Namdaroglu, S; Karakus, A; Karakus, V; Pamuk, GE; Altuntas, F; Sari, HI; Ozet, G; Aydogdu, I; Okan, V; Kaya, E; Yildirim, R; Yildizhan, E; Ozgur, G; Ozcebe, OI; Payzin, B; Akpinar, S; Demirkan, F (2016)
  • A Multicenter Experience of Thrombotic Microangiopathies in Turkey: The 
    Tekgunduz, E; Yilmaz, M; Erkurt, MA; Kiki, I; Kaya, AH; Kaynar, L; Alacacioglu, I; Cetin, G; Ozarslan, I; Kuku, I; Sincan, G; Salim, O; Namdaroglu, S; Karakus, A; Karakus, V; Pamuk, GE; Altuntas, F; Sari, HI; Ozet, G; Aydogdu, I; Okan, V; Kaya, E; Yildirim, R; Yildizhan, E; Ozgur, G; Ozcebe, OI; Payzin, B; Akpinar, S; Demirkan, F (2016)
  • A multicenter experience of thrombotic microangiopathies in Turkey: The 
    Tekgunduz, E; Yilmaz, M; Erkurt, MA; Kiki, I; Kaya, AH; Kaynar, L; Alacacioglu, I; Cetin, G; Ozarslan, I; Kuku, I; Sincan, G; Salim, O; Namdaroglu, S; Karakus, A; Karakus, V; Altuntas, F; Sari, I; Ozet, G; Aydogdu, I; Okan, V; Kaya, E; Yildirim, R; Yildizhan, E; Ozgur, G; Ozcebe, OI; Payzin, B; Akpinar, S; Demirkan, F (2018)
    Thrombotic microangiopathies (TMAs) are rare, but life-threatening disorders characterized by microangiopathic hemolytic anemia and thrombocytopenia (MAHAT) associated with multiorgan dysfunction as a result of microvascular ...
  • A multicenter experience of thrombotic microangiopathies in Turkey: The 
    Tekgunduz, E; Yilmaz, M; Erkurt, MA; Kiki, I; Kaya, AH; Kaynar, L; Alacacioglu, I; Cetin, G; Ozarslan, I; Kuku, I; Sincan, G; Salim, O; Namdaroglu, S; Karakus, A; Karakus, V; Altuntas, F; Sari, I; Ozet, G; Aydogdu, I; Okan, V; Kaya, E; Yildirim, R; Yildizhan, E; Ozgur, G; Ozcebe, OI; Payzin, B; Akpinar, S; Demirkan, F (2018)
    Thrombotic microangiopathies (TMAs) are rare, but life-threatening disorders characterized by microangiopathic hemolytic anemia and thrombocytopenia (MAHAT) associated with multiorgan dysfunction as a result of microvascular ...
  • A Multi-Center Study on the Efficacy of Eltrombopag in Management of 
    Cekdemir, D; Guvenc, S; Ozdemirkiran, F; Eser, A; Topts, T; Ozkocaman, V; Sahin, HH; Turak, EE; Esen, R; Comert, M; Sadrilo, S; Aslaner, M; Ulu, BU; Karakus, A; Bapur, DS; Alacacioglu, I; Aydin, D; Tekinalp, A; Namdaroglu, S; Ceran, F; Tarkun, P; Kiper, D; Cetiner, M; Yenerel, M; Demir, AM; Yilmaz, G; Terzi, H; Atilla, E; Malkan, UY; Acar, K; Ozturk, E; Tombak, A; Sunu, C; Salim, O; Alayvaz, N; Sayan, O; Ozan, U; Ayer, M; Gokgoz, Z; Andic, N; Kizilkilic, E; Noyan, F; Ozen, M; Tanrikulu, FP; Alanoglu, G; Ozkan, HA; Aslan, V; Cetin, G; Erikci, AA; Deveci, B; Dursun, FE; Dermenci, H; Aytan, P; Gunduz, M; Karakus, V; Ozlu, C; Demircioglu, S; Yanar, OMA; Ozatli, D; Undar, L; Tiftik, EN; Sucak, EGT; Haznedaroglu, I; Ozcan, M; Sencan, M; Tombuloglu, M; Ozet, G; Bilgir, O; Turgut, B; Ozcan, MA; Payzin, KB; Sonmez, M; Ayyildiz, E; Dal, MS; Ertop, S; Turgut, M; Soysal, T; Kaya, E; Unal, A; Pehlivan, M; Atagunduz, I; Firatli, TT; Saydam, G; Kucukkaya, RD (2019)
    Objective: The aim of the present study was to evaluate the efficacy and safety of eltrombopag, an oral thrombopoietin receptor agonist, in patients with chronic immune thrombocytopenia (ITP).
  • A Multi-Center Study on the Efficacy of Eltrombopag in Management of 
    Cekdemir, D; Guvenc, S; Ozdemirkiran, F; Eser, A; Topts, T; Ozkocaman, V; Sahin, HH; Turak, EE; Esen, R; Comert, M; Sadrilo, S; Aslaner, M; Ulu, BU; Karakus, A; Bapur, DS; Alacacioglu, I; Aydin, D; Tekinalp, A; Namdaroglu, S; Ceran, F; Tarkun, P; Kiper, D; Cetiner, M; Yenerel, M; Demir, AM; Yilmaz, G; Terzi, H; Atilla, E; Malkan, UY; Acar, K; Ozturk, E; Tombak, A; Sunu, C; Salim, O; Alayvaz, N; Sayan, O; Ozan, U; Ayer, M; Gokgoz, Z; Andic, N; Kizilkilic, E; Noyan, F; Ozen, M; Tanrikulu, FP; Alanoglu, G; Ozkan, HA; Aslan, V; Cetin, G; Erikci, AA; Deveci, B; Dursun, FE; Dermenci, H; Aytan, P; Gunduz, M; Karakus, V; Ozlu, C; Demircioglu, S; Yanar, OMA; Ozatli, D; Undar, L; Tiftik, EN; Sucak, EGT; Haznedaroglu, I; Ozcan, M; Sencan, M; Tombuloglu, M; Ozet, G; Bilgir, O; Turgut, B; Ozcan, MA; Payzin, KB; Sonmez, M; Ayyildiz, E; Dal, MS; Ertop, S; Turgut, M; Soysal, T; Kaya, E; Unal, A; Pehlivan, M; Atagunduz, I; Firatli, TT; Saydam, G; Kucukkaya, RD (2019)
    Objective: The aim of the present study was to evaluate the efficacy and safety of eltrombopag, an oral thrombopoietin receptor agonist, in patients with chronic immune thrombocytopenia (ITP).
  • Convalescent plasma therapy in patients withCOVID-19 
    Yigenoglu, TN; Hacibekiroglu, T; Berber, I; Dal Sinan, M; Basturk, A; Namdaroglu, S; Korkmaz, S; Ulas, T; Dal, T; Erkurt, MA; Turgut, B; Altuntas, F (2020)
    There are currently no licensed vaccines or therapeutics for COVID-19. Anti-SARS CoV-2 antibody-containing plasmas, obtained from the recovered individuals who had confirmed COVID-19, have been started to be collected using ...
  • Convalescent plasma therapy in patients withCOVID-19 
    Yigenoglu, TN; Hacibekiroglu, T; Berber, I; Dal Sinan, M; Basturk, A; Namdaroglu, S; Korkmaz, S; Ulas, T; Dal, T; Erkurt, MA; Turgut, B; Altuntas, F (2020)
    There are currently no licensed vaccines or therapeutics for COVID-19. Anti-SARS CoV-2 antibody-containing plasmas, obtained from the recovered individuals who had confirmed COVID-19, have been started to be collected using ...
  • Convalescent plasma therapy in patients withCOVID-19 
    Yigenoglu, TN; Hacibekiroglu, T; Berber, I; Dal Sinan, M; Basturk, A; Namdaroglu, S; Korkmaz, S; Ulas, T; Dal, T; Erkurt, MA; Turgut, B; Altuntas, F (2020)
    There are currently no licensed vaccines or therapeutics for COVID-19. Anti-SARS CoV-2 antibody-containing plasmas, obtained from the recovered individuals who had confirmed COVID-19, have been started to be collected using ...
  • Splenic Marginal Zone Lymphoma in Turkey: Association with Hepatitis B 
    Okay, M; Aslan, T; Ozdemir, E; Uner, A; Saglam, A; Gungor, E; Uysal, A; Aslan, NA; Yildizhan, E; Agit, A; Dal, MS; Korkmaz, S; Namdaroglu, S; Sivgin, S; Cagliyan, GA; Demircioglu, S; Barista, I; Ozhamam, E; Vural, F; Eser, B; Ozet, G; Yildirim, R; Dogu, MH; Berber, I; Erkurt, MA; Malkan, UY; Altuntas, F; Buyukasik, Y (2020)
    Objective: Chronic antigenic stimulation is frequently blamed in the pathogenesis of extranodal marginal zone lymphomas including splenic marginal zone lymphoma (SMZL). Chronic hepatitis C is frequently observed in SMZL ...
  • Outcome of COVID-19 in patients with chronic myeloid leukemia receiving 
    Basci, S; Ata, N; Altuntas, F; Yigenoglu, TN; Dal, MS; Korkmaz, S; Namdaroglu, S; Basturk, A; Hacibekiroglu, T; Dogu, MH; Berber, I; Dal, K; Erkurt, MA; Turgut, B; Caglayan, M; Ayvali, MO; Celik, O; Ulgu, MM; Birinci, S (2020)
    Introduction In this study, we aim to report the outcome of COVID-19 in chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitor (TKI). Method The data of 16 laboratory-confirmed COVID-19 patients with ...
  • Convalescent plasma therapy in patients withCOVID-19 
    Yigenoglu, TN; Hacibekiroglu, T; Berber, I; Dal Sinan, M; Basturk, A; Namdaroglu, S; Korkmaz, S; Ulas, T; Dal, T; Erkurt, MA; Turgut, B; Altuntas, F (2020)
    There are currently no licensed vaccines or therapeutics for COVID-19. Anti-SARS CoV-2 antibody-containing plasmas, obtained from the recovered individuals who had confirmed COVID-19, have been started to be collected using ...
  • Splenic Marginal Zone Lymphoma in Turkey: Association with Hepatitis B 
    Okay, M; Aslan, T; Ozdemir, E; Uner, A; Saglam, A; Gungor, E; Uysal, A; Aslan, NA; Yildizhan, E; Agit, A; Dal, MS; Korkmaz, S; Namdaroglu, S; Sivgin, S; Cagliyan, GA; Demircioglu, S; Barista, I; Ozhamam, E; Vural, F; Eser, B; Ozet, G; Yildirim, R; Dogu, MH; Berber, I; Erkurt, MA; Malkan, UY; Altuntas, F; Buyukasik, Y (2020)
    Objective: Chronic antigenic stimulation is frequently blamed in the pathogenesis of extranodal marginal zone lymphomas including splenic marginal zone lymphoma (SMZL). Chronic hepatitis C is frequently observed in SMZL ...
  • Convalescent plasma therapy in patients withCOVID-19 
    Yigenoglu, TN; Hacibekiroglu, T; Berber, I; Dal Sinan, M; Basturk, A; Namdaroglu, S; Korkmaz, S; Ulas, T; Dal, T; Erkurt, MA; Turgut, B; Altuntas, F (2020)
    There are currently no licensed vaccines or therapeutics for COVID-19. Anti-SARS CoV-2 antibody-containing plasmas, obtained from the recovered individuals who had confirmed COVID-19, have been started to be collected using ...